Liu Ying, She Lan-Hui, Wang Xiang-Yang, Zhang Geng-Lin, Yan Ying, Lin Chao-Shuang, Zhao Zhi-Xin, Gao Zhi-Liang
Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University Guangzhou 510630, China.
Intranet of Guangzhou Woman and Children's Medical Center Guangzhou, China.
Int J Clin Exp Med. 2014 Apr 15;7(4):998-1004. eCollection 2014.
Myeloid-derived suppressor cells (MDSCs) are one of the most important regulators of anti-tumor T-cell responses in cancers. This study aimed to investigate MDSCs in the peripheral blood of patients with chronic hepatitis C (CHC) before and after 4-week treatment with pegylated interferon (PEG-IFN) and ribavirin, and to evaluate their correlation with CD4(+)CD25(high) regulatory T cells (Tregs) and clinical parameters. A total of 80 patients with CHC were enrolled into this study, 37 of whom were treated with PEG-IFN and ribavirin. Compared with healthy controls (0.462% [range 0.257%-0.634%]), the proportion of MDSCs in the peripheral blood of 80 CHC patients (0.601% [range 0.333%-1.027%]) increased significantly before therapy (P=0.011). For 37 HCV patients, the proportion of circulating MDSCs (0 w: 0.597% [range 0.296%-1.021%], 4 w: 0.126% [0.066%-0.239%], P<0.01) and Tregs (0 w: 2.467±0.927%, 4 w: 2.074±0.840%, P=0.047) decreased significantly after 4-week antiviral treatment. No significant correlation was found between MDSCs and Tregs. These findings suggest that MDSCs expand in the peripheral blood of CHC patients, but decrease after 4-week antiviral treatment.
髓源性抑制细胞（MDSCs）是癌症中抗肿瘤T细胞反应的最重要调节因子之一。本研究旨在调查慢性丙型肝炎（CHC）患者在接受聚乙二醇干扰素（PEG-IFN）和利巴韦林治疗4周前后外周血中的MDSCs，并评估它们与CD4(+)CD25(high)调节性T细胞（Tregs）及临床参数的相关性。共有80例CHC患者纳入本研究，其中37例接受PEG-IFN和利巴韦林治疗。与健康对照者（0.462%[范围0.257%-0.634%]）相比，80例CHC患者治疗前外周血中MDSCs的比例（0.601%[范围0.333%-1.027%]）显著升高（P=0.011）。对于37例丙型肝炎病毒（HCV）患者，抗病毒治疗4周后，循环MDSCs的比例（0周：0.597%[范围0.296%-1.021%]，4周：0.126%[0.066%-0.239%]，P<0.01）和Tregs的比例（0周：2.467±0.927%，4周：2.074±0.840%，P=0.047）显著降低。未发现MDSCs与Tregs之间存在显著相关性。这些发现表明，MDSCs在CHC患者外周血中增多，但在抗病毒治疗4周后减少。
